Erratum to: The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK Á BenedictL VerdianG Maclaine Erratum 11 October 2012 Pages: 1014 - 1014
QALYs and Carers Hareth Al-JanabiTerry N. FlynnJoanna Coast Current Opinion 11 October 2012 Pages: 1015 - 1023
Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease Judith DamsBernhard BornscheinRichard Dodel Review Article 11 October 2012 Pages: 1025 - 1049
Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy Rumona DicksonAdrian BagustVidhya Sagar Ramani Review Article 11 October 2012 Pages: 1051 - 1062
Cost-Effectiveness Analysis of Prophylactic Lamivudine Use in Preventing Vertical Transmission of Hepatitis B Virus Infection Hui-Fang HungHsiu-Hsi Chen Original Research Article 11 October 2012 Pages: 1063 - 1073
Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective Helen DakinMorris ShermanAnthony Bentley Original Research Article 11 October 2012 Pages: 1075 - 1091